Israeli scientist finds a way to cure deadly brain cancer


Israeli scientist finds a way to cure deadly brain cancer. Tel Aviv University (TAU) have announced a groundbreaking discovery in understanding and treating one of the most lethal brain cancers, Glioblastoma.

“Glioblastoma is the deadliest type of cancer in the central nervous system, accounting for most malignant brain tumours,” said Prof. Ronit Satchi-Fainaro, Director of the Cancer Biology Research Center and the Head of the Cancer Research at Tel Aviv University.

Israeli scientist finds a way to cure deadly brain cancer

“It is aggressive, invasive, and fast-growing, making it resistant to existing treatments, with patients dying within a year of cancer’s onset. Moreover, Glioblastoma is defined as a ‘cold tumour,’ which means that it does not respond to immunotherapeutic attempts to activate the immune system against it.”

Just 40% of Glioblastoma patients survive a year after diagnosis, and only 5% survive five years, along with surgery, radiotherapy, and chemotherapy.

Initially, the researchers found an unexpected defect in the brain’s immune system that, rather than regulating the spread of cancer cells, aided cell division and spread of Glioblastoma cancer cells.

Also Read: Poor woman suffering from cancer gets free treatment on UP HC’s orders

This was partially due to the release of P-selectin (SELP), a protein that usually aids cell movement inside the body.

Researchers were able to inhibit the secretion of the SELP protein in the next stage after identifying the problem, neutralizing the immune system’s breakdown, restoring its normal function, and stopping the spread of this incurable aggressive cancer.

The Tel Aviv University team worked with the Tel Aviv Sourasky Medical Center, which provided Glioblastoma tissue samples obtained during surgery, as well as neurosurgeons from Johns Hopkins University and the Lieber Institute in the United States, who provided stable brain tissues obtained from autopsies.

Satchi-Fainaro suggests that the research may have life-saving medicinal effects and that now that the drug inhibiting SELP is effective in humans, a clinical trial could be approved reasonably quickly.


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Latest stories

In these dark times, here are 5 stories that show us how kindness is above everything else

From a Gadag SP helping migrants to a women's group serving nutritious food to Covid patients in home quarantine in Andhra Pradesh, these five stories give us hope and tell us how kindness and compassion are above everything else in the world.

Kerala’s Sarandev creates eco-friendly illuminated portraits for the first time, makes record

Sarandev's eco-friendly illuminated portraits sets three records. This 25-year-old aims to create a unique art by blending lights and...

May 8-May 15: 8 events that should have made the headlines this week but didn’t

Here are 8 important news pieces which we think should have been in the headlines this week but they didn't.

From toddler to 110-year-old, here are four instances of incredible Covid recoveries

Covid recoveries of people in the present day scenario is a ray of hope. Today let us read the...

Whats Trending

#MumbaiRains trends as Cyclone Tauktae nears, intensifies into extremely severe cyclonic storm

Mumbai rains started trending on Twitter after Cyclone Tauktae gets severe in the region.

Mallika Dua receives prompt response from not one but two politicians; hypocrisy at its best?

Mallika Dua took to Twitter to ask for help and well, her COVID-19 SOS call received a response rather quickly. Read on Platocast.

Here’s why #dhruvrathee is trending on Twitter

Dhruv Rathee gets slammed for his new video on Israel vs Palestine. Read the article to know why #dhruvrathee is trending on Twitter

May 15 last date to accept WhatsApp’s new privacy policy, here’s how netizens are reacting

WhatsApp users have 24 hours to accept the new privacy policy by WhatsApp, post-deadline you won't be able to access some features.